From WikiProjectMed
Jump to navigation Jump to search
Trade namesDoryx, Doxyhexal, Doxylin among others
  • (4S,4aR,5S,5aR,6R,12aS)-4-(Dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
Clinical data
  • AU: D
  • US: D (Evidence of risk)
Routes of
By mouth, IV[1]
Defined daily dose100 mg (by mouth or by injection)[2]
External links
AHFS/Drugs.comSystemic: Monograph
Mouth: Monograph
License data
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
Protein binding80–90%
Elimination half-life10–22 hours
ExcretionMainly faeces, 40% urine
Chemical and physical data
Molar mass444.440 g·mol−1
3D model (JSmol)
  • CN(C)[C@@H]3C(\O)=C(\C(N)=O)C(=O)[C@@]4(O)C(/O)=C2/C(=O)c1c(cccc1O)[C@H](C)[C@H]2[C@H](O)[C@@H]34
  • InChI=1S/C22H24N2O8.H2O/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29;/h4-7,10,14-15,17,25,27-29,32H,1-3H3,(H2,23,31);1H2/t7-,10+,14+,15-,17-,22-;/m0./s1 checkY

Doxycycline is an antibiotic used in the treatment of infections caused by bacteria and certain parasites.[1] It is used to treat bacterial pneumonia, acne, chlamydia infections, early Lyme disease, cholera, typhus, and syphilis.[1] It is also used to prevent malaria and in combination with quinine, to treat malaria.[1] Doxycycline may be taken by mouth or by injection into a vein.[1]

Common side effects include diarrhea, nausea, vomiting, and an increased risk of sunburn.[1] There have been concerns in the first trimester of pregnancy or in young children may result in permanent discoloration of the teeth.[1] Though in children this does not occur with normal doses.[3] Its use during breastfeeding is probably safe.[1] Doxycycline is a broad-spectrum antibiotic, of the tetracycline class.[1] Like other agents of this class, it either slows or kills bacteria by inhibiting protein production.[1][4] It kills malaria by targeting a plastid organelle, the apicoplast.[5][6]

Doxycycline was patented in 1957 and came into commercial use in 1967.[7][8] It is on the World Health Organization's List of Essential Medicines.[9] Doxycycline is available as a generic medicine and is generally inexpensive.[1][10] The wholesale cost in the developing world is between US$0.01 and US$0.04 per pill.[11] In the United States, ten days of treatment has a wholesale costs of about US$3.40 as of 2019.[12] However, in 2014, due to supply issues, it was being sold for as much as US$60–200 for that amount.[1][13] In 2017, it was the 113th most commonly prescribed medication in the United States, with more than six million prescriptions.[14][15]

Medical use

Generic 100 mg doxycycline capsules
Doxycycline package

In addition to the general indications for all members of the tetracycline antibiotics group, doxycycline is frequently used to treat Lyme disease, chronic prostatitis, sinusitis, pelvic inflammatory disease,[16][17] acne, rosacea,[18][19] and rickettsial infections.[20] It is in the 'access' group of the WHO AWaRe Classification.[21]

In Canada, in 2004, doxycycline was considered a first-line treatment for chlamydia and non-gonococcal urethritis and with cefixime for uncomplicated gonorrhea.[22]


Moraxella catarrhalis, Brucella melitensis, Chlamydia pneumoniae, and Mycoplasma pneumoniae are generally susceptible to doxycycline, while some Haemophilus spp., Mycoplasma hominis, and Pseudomonas aeruginosa have developed resistance to varying degrees.[23]

It is used in the treatment and prophylaxis of anthrax and Leptospirosis.[24] It is also effective against Yersinia pestis (the infectious agent of bubonic plague), and is prescribed for the treatment of Lyme disease,[25][26][27][28] ehrlichiosis,[29][30] and Rocky Mountain spotted fever.[31]

Doxycycline is indicated for treatment of:[31][32]

When bacteriologic testing indicates appropriate susceptibility to the drug, doxycycline may be used to treat these infections caused by Gram-negative bacteria:[31][32]

Some Gram-positive bacteria have developed resistance to doxycycline. Up to 44% of Streptococcus pyogenes and up to 74% of S. faecalis specimens have developed resistance to the tetracycline group of antibiotics. Up to 57% of P.acnes strains developed resistance to doxycycline.[36] When bacteriologic testing indicates appropriate susceptibility to the drug, doxycycline may be used to treat these infections caused by Gram-positive bacteria:[31][32]

When penicillin is contraindicated, doxycycline can be used to treat:[31][32]

  • Syphilis caused by Treponema pallidum
  • Yaws caused by Treponema pertenue
  • Listeriosis due to Listeria monocytogenes
  • Vincent's infection caused by Fusobacterium fusiforme
  • Actinomycosis caused by Actinomyces israelii
  • Infections caused by Clostridium species

Doxycycline may also be used as adjunctive therapy for severe acne.[31][32]

The first-line treatment for brucellosis is a combination of doxycycline and streptomycin and the second-line is a combination of doxycycline and rifampicin (rifampin).[37]


Doxycycline is active against the erythrocytic stages of Plasmodium falciparum but not against the gametocytes of Plasmodium falciparum.[38] It is used to prevent malaria.[39] It is not recommended alone for initial treatment of malaria, even when the parasite is doxycycline-sensitive, because the antimalarial effect of doxycycline is delayed.[40]

The World Health Organization (WHO) guidelines state that the combination of doxycycline with either artesunate or quinine may be used for the treatment of uncomplicated malaria due to Plasmodium falciparum or following intravenous treatment of severe malaria.[41]


Doxycycline kills the symbiotic Wolbachia bacteria in the reproductive tracts of parasitic filarial nematodes, making the nematodes sterile, and thus reducing transmission of diseases such as onchocerciasis and elephantiasis.[42] Field trials in 2005 showed an eight-week course of doxycycline almost completely eliminates the release of microfilariae.[43]

Spectrum of susceptibility

Doxycycline has been used successfully to treat sexually transmitted, respiratory, and ophthalmic infections. Representative pathogenic genera include Chlamydia, Streptococcus, Ureaplasma, Mycoplasma, and others. The following represents MIC susceptibility data for a few medically significant microorganisms.[44]

  • Chlamydia psittaci: 0.03 μg/mL
  • Mycoplasma pneumoniae: 0.016 μg/mL — 2 μg/mL
  • Streptococcus pneumoniae: 0.06 μg/mL — 32 μg/mL


Doxycycline is also used for sclerotherapy in slow-flow vascular malformations, namely venous and lymphatic malformations, as well as post-operative lymphoceles.[45]


The defined daily dose is 100 mg (by mouth or by injection).[2] The typical dose in adults is 100 mg once to twice per day for 5 to 14 days.[46] Though certain conditions may require longer courses of treatment.[46]

In children the the dose is typically 1 to 2 mg/kg twice per day.[47] Instructions are available on how to make this dose from tablets.[48] In those under 8 years old, less than 21 days are recommended due to potential effects on the teeth.[47]

For malaria prevention in those who weight less than 40 kg the dose is 50 mg once per day while in those who weight more than 50 kg the dose is 100 mg once per day.[47]

Side effects

Side effects are similar to those of other members of the tetracycline antibiotic group. Doxycycline can cause gastrointestinal upset.[49][50] Doxycycline by mouth can cause pill esophagitis, particularly when it is swallowed without adequate fluid, or by persons with difficulty swallowing or impaired mobility.[51] Doxycycline is less likely than other antibiotic drugs to cause Clostridium difficile colitis.[52]

An red rash in sun-exposed parts of the body has been reported in 7–21% of persons taking doxycycline for malaria prevention. One study examined the tolerability of various malaria preventative regimens and found doxycycline did not cause a higher percentage of all skin events (photosensitivity not specified) when compared with other antimalarials. The rash resolves upon discontinuation of the drug.[53]

Unlike some other members of the tetracycline group, it may be used in those with kidney problems.[54]

Pregnancy and lactation

Doxycycline is categorized by the FDA as a class D drug in pregnancy. Doxycycline crosses into breastmilk.[55] Other tetracycline antibiotics are contraindicated in pregnancy and up to eight years of age, due to the potential for disrupting bone and tooth development.[56] They include a class warning about staining of teeth and decreased development of dental enamel in children exposed to tetracyclines in utero, during breastfeeding or during young childhood.[57] However, the FDA has acknowledged that the actual risk of dental staining of primary teeth is undetermined for doxycycline specifically. The best available evidence indicates that doxycycline has little or no effect on hypoplasia of dental enamel or on staining of teeth and the CDC recommends the use of doxycycline for treatment of Q fever and also for tick-borne rickettsial diseases in young children and others advocate for its use in malaria.[58][3]


Other contraindications are severe liver disease and concomitant use of isotretinoin or other retinoids, as both tetracyclines and retinoids can cause intracranial hypertension (increased pressure around the brain) in rare cases.[59]


The combination of doxycycline with dairy, antacids, calcium supplements, iron products, laxatives containing magnesium, or bile acid sequestrants is not inherently dangerous, but any of these foods and supplements may decrease doxycycline's effectiveness.[59][60]

Breakfast was observed to reduce doxycycline absorption significantly. Absorption of tetracycline occurs in the stomach and the upper small intestine. Absorption of tetracyclines has been reported to be impaired by milk products, aluminum hydroxide gels, sodium bicarbonate, calcium and magnesium salts, laxatives containing magnesium and iron preparations. The mechanisms responsible for decreased absorption appear to be chelation and an increase in gastric pH. ... In view of these results, it is advisable to instruct the patients to take doxycycline on an empty stomach.[61]

Previously, doxycycline was believed to impair the effectiveness of many types of hormonal contraception due to CYP450 induction. Research has shown no significant loss of effectiveness in oral contraceptives while using most tetracycline antibiotics (including doxycycline), although many physicians still recommend the use of barrier contraception for people taking the drug to prevent unwanted pregnancy.[62][63][64]


Doxycycline, like other tetracycline antibiotics, is bacteriostatic. It works by preventing bacteria from reproducing through the inhibition of protein synthesis.[65]

Doxycycline is highly lipophilic so can easily enter cells, meaning the drug is easily absorbed after oral administration and has a large volume of distribution. It can also be re-absorbed in the renal tubules and gastrointestinal tract due to its high lipophillicity so has a long elimination half life, and does not accumulate in the kidneys of patients with kidney failure due to the compensatory excretion in faeces.[50][66] Doxycycline–metal ion complexes are unstable at acid pH, therefore more doxycycline enters the duodenum for absorption than the earlier tetracycline compounds. In addition, food has less effect on absorption than on absorption of earlier drugs with doxycycline serum concentrations being reduced by about 20% by test meals compared with 50% for tetracycline.[67]

Mechanism of action

Doxycycline is a broad spectrum antibiotic. It inhibits the synthesis of bacterial proteins by binding to the 30S ribosomal subunit, which is only found in bacteria.[49][66] This prevents the binding of transfer RNA to messenger RNA at the ribosomal subunit meaning amino acids cannot be added to polypeptide chains and new proteins cannot be made. This stops bacterial growth giving the immune system time to kill and remove the bacteria.[68]


The substance is almost completely absorbed from the upper part of the small intestine. It reaches highest concentrations in the blood plasma after one to two hours and has a high plasma protein binding rate of about 80–90%. Doxycycline penetrates into almost all tissues and body fluids. Very high concentrations are found in the gallbladder, liver, kidneys, lung, breast milk, bone and genitals; low ones in saliva, aqueous humour, cerebrospinal fluid, and especially in inflamed meninges.[59][69][70]

Doxycycline metabolism is negligible. It is actively excreted into the gut (in part via the gallbladder), where some of it is inactivated by forming chelates. About 40% are eliminated via the kidneys, much less in people with end-stage kidney disease. The biological half-life is 18 to 22 hours (16±6 hours according to another source[69]) in healthy people, slightly longer in those with end-stage kidney disease, and significantly longer in those with liver disease.[59][69][70]


Expired tetracyclines or tetracyclines allowed to stand at a pH less than 2 are reported to be nephrotoxic due to the formation of a degradation product, anhydro-4-epitetracycline[71][72] causing Fanconi syndrome.[73] In the case of doxycycline, the absence of a hydroxyl group in C-6 prevents the formation of the nephrotoxic compound.[72] Nevertheless, tetracyclines and doxycycline itself have to be taken with caution in patients with kidney injury, as they can worsen azotemia due to catabolic effects.[73]


After penicillin revolutionized the treatment of bacterial infections in WWII, many chemical companies moved into the field of discovering antibiotics by bioprospecting. American Cyanamid was one of these, and in the late 1940s chemists there discovered chlortetracycline, the first member of the tetracycline class of antibiotics.[74] Shortly thereafter, scientists at Pfizer discovered terramycin and it was brought to market. Both compounds, like penicillin, were natural products and it was commonly believed that nature had perfected them, and further chemical changes could only degrade their effectiveness. Scientists at Pfizer led by Lloyd Conover modified these compounds, which led to the invention of tetracycline itself, the first semi-synthetic antibiotic. Charlie Stephens' group at Pfizer worked on further analogs and created one with greatly improved stability and pharmacological efficacy: doxycycline. It was clinically developed in the early 1960s and approved by the FDA in 1967.[74]

As its patent grew near to expiring in the early 1970s, the patent became the subject of lawsuit between Pfizer and International Rectifier[75] that was not resolved until 1983; at the time it was the largest litigated patent case in US history.[76] Instead of a cash payment for infringement, Pfizer took the veterinary and feed-additive businesses of International Rectifier's subsidiary, Rachelle Laboratories.[76]

In January 2013, the FDA reported shortages of some, but not all, forms of doxycyline "caused by increased demand and manufacturing issues".[77] Companies involved included an unnamed major generics manufacturer that ceased production in February 2013, Teva (which ceased production in May 2013), Mylan, Actavis, and Hikma Pharmaceuticals.[78][79] The shortage came at a particularly bad time, since there were also shortages of an alternative antibiotic, tetracycline, at the same time.[80] The market price for doxycycline dramatically increased in the United States in 2013 and early 2014 (from $20 to over $1800 for a bottle of 500 tablets),[81][82][83] before decreasing again.[84][85]

The wholesale cost in the developing world in 2015 was between US$0.01 and US$0.04 per pill.[11] In the United States, ten days of treatment has a wholesale costs of about US$3.40 as of 2019.[86] However, in 2014, due to supply issues, it was being sold for as much as US$60.00–200.00 for that amount.[1][13]

Society and culture


Doxycycline is available worldwide under many brand names.[87] Doxycycline is available as a generic medicine and is generally inexpensive.[1][10] The wholesale cost is between US$0.01 and $0.04 per pill.[11] As of 2020, 10 tablets of doxycycline 100mg costs the NHS in the UK around £1.50.[88]


Doxycycline is available as tablets and capsules.[88] An suspension and solution that can be taken by mouth can be specially ordered.[88]


Tet-ON inducible shRNA system

In chronic obstructive pulmonary disease, doxycycline has been shown to improve lung functions in people with stable symptoms.[89]

Other experimental applications include:

Research reagent

Doxycycline and other members of the tetracycline class of antibiotics are often used as research reagents in in vitro and in vivo biomedical research experiments involving bacteria as well in experiments in eukaryotic cells and organisms with inducible protein expression systems using tetracycline-controlled transcriptional activation. The mechanism of action for the antibacterial effect of tetracyclines relies on disrupting protein translation in bacteria, thereby damaging the ability of microbes to grow and repair; however protein translation is also disrupted in eukaryotic mitochondria impairing metabolism and leading to effects that can confound experimental results.[100][101] Doxycycline is also used in "tet-on" (gene expression activated by doxycycline) and "tet-off" (gene expression inactivated by doxycycline) tetracycline-controlled transcriptional activation to regulate transgene expression in organisms and cell cultures.[102] Doxycycline is more stable than tetracycline for this purpose.[102] At subantimicrobial doses, doxycycline is an inhibitor of matrix metalloproteases, and has been used in various experimental systems for this purpose, such as for recalcitrant recurrent corneal erosions.[103]


  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 "Doxycycline calcium". The American Society of Health-System Pharmacists. Archived from the original on 23 September 2015. Retrieved 18 August 2015.
  2. 2.0 2.1 "WHOCC - ATC/DDD Index". Archived from the original on 2 July 2020. Retrieved 22 September 2020.
  3. 3.0 3.1 Ravindra, D; Huang, G; Hallett, K; Burgner, DP; Gwee, A; Silva, MJ (1 July 2023). "Antibiotic Exposure and Dental Health: A Systematic Review". Pediatrics. 152 (1). doi:10.1542/peds.2023-061350. PMID 37264510.
  4. Nelson, ML; Levy, SB (December 2011). "The history of the tetracyclines". Annals of the New York Academy of Sciences. 1241 (1): 17–32. Bibcode:2011NYASA1241...17N. doi:10.1111/j.1749-6632.2011.06354.x. PMID 22191524.
  5. McFadden GI (March 2014). "Apicoplast". Curr. Biol. 24 (7): R262–3. doi:10.1016/j.cub.2014.01.024. PMID 24698369.
  6. Schlagenhauf-Lawlor, Patricia (2008). Travelers' Malaria. PMPH-USA. p. 148. ISBN 9781550093360. Archived from the original on 1 August 2020. Retrieved 18 August 2019.
  7. Fischer, Janos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 489. ISBN 9783527607495. Archived from the original on 1 August 2020. Retrieved 9 September 2017.
  8. Corey, E.J. (2013). Drug discovery practices, processes, and perspectives. Hoboken, N.J.: John Wiley & Sons. p. 406. ISBN 9781118354469. Archived from the original on 1 August 2020. Retrieved 9 September 2017.
  9. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  10. 10.0 10.1 Hamilton, Richard J. (2011). Tarascon pharmacopoeia (12th ed.). Sudbury, MA: Jones & Bartlett Learning. p. 79. ISBN 9781449600679. Archived from the original on 1 August 2020. Retrieved 9 September 2017.
  11. 11.0 11.1 11.2 "Doxycycline". International Medical Products Price Guide. Archived from the original on 30 March 2019. Retrieved 16 January 2018.
  12. "NADAC as of 2019-09-11 |". Centers for Medicare and Medicaid Services. Archived from the original on 30 December 2019. Retrieved 10 September 2019.
  13. 13.0 13.1 "Officials Question the Rising Costs of Generic Drugs". New York Times. 7 October 2014. Archived from the original on 28 October 2015. Retrieved 22 September 2015.
  14. "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
  15. "Doxycycline - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 11 April 2020.
  16. Sweet RL, Schachter J, Landers DV, Ohm-Smith M, Robbie MO (1988). "Treatment of hospitalized patients with acute pelvic inflammatory disease: comparison of cefotetan plus doxycycline and ana doxycycline". Am. J. Obstet. Gynecol. 158 (3 Pt 2): 736–41. doi:10.1016/S0002-9378(16)44537-0. PMID 3162653.
  17. Gjønnaess H, Holten E (1978). "Doxycycline (Vibramycin) in pelvic inflammatory disease". Acta Obstet Gynecol Scand. 57 (2): 137–9. doi:10.3109/00016347809155893. PMID 345730.
  18. Määttä M, Kari O, Tervahartiala T, et al. (2006). "Tear fluid levels of MMP-8 are elevated in ocular rosacea—treatment effect of oral doxycycline". Graefes Arch. Clin. Exp. Ophthalmol. 244 (8): 957–62. doi:10.1007/s00417-005-0212-3. PMID 16411105.
  19. Quarterman MJ, Johnson DW, Abele DC, Lesher JL, Hull DS, Davis LS (1997). "Ocular rosacea. Signs, symptoms, and tear studies before and after treatment with doxycycline". Arch Dermatol. 133 (1): 49–54. doi:10.1001/archderm.133.1.49. PMID 9006372.
  20. Walker DH, Paddock CD, Dumler JS (November 2008). "Emerging and re-emerging tick-transmitted rickettsial and ehrlichial infections". Med. Clin. North Am. 92 (6): 1345–61, x. doi:10.1016/j.mcna.2008.06.002. PMID 19061755.
  21. Zanichelli, Veronica; Sharland, Michael; Cappello, Bernadette; Moja, Lorenzo; Getahun, Haileyesus; Pessoa-Silva, Carmem; Sati, Hatim; van Weezenbeek, Catharina; Balkhy, Hanan; Simão, Mariângela; Gandra, Sumanth; Huttner, Benedikt (1 April 2023). "The WHO AWaRe (Access, Watch, Reserve) antibiotic book and prevention of antimicrobial resistance". Bulletin of the World Health Organization. 101 (4): 290–296. doi:10.2471/BLT.22.288614. ISSN 0042-9686. Archived from the original on 7 May 2023. Retrieved 17 November 2023.
  22. Michael L. Rekart (December 2014). "Doxycycline: "New" treatment of choice for genital chlamydia infections". Archived from the original on 2 February 2017.
  23. "Doxycycline spectrum of bacterial susceptibility and Resistance" (PDF). Archived from the original (PDF) on 1 February 2014. Retrieved 4 May 2012.
  24. Stoddard, Robyn A.; Galloway, Renee L.; Guerra, Marta A. (10 July 2015). "Leptospirosis - Chapter 3". Atlanta, GA: Centers for Disease Control and Prevention. Archived from the original on 9 April 2017. Retrieved 16 April 2017.
  25. Nadelman RB, Luger SW, Frank E, Wisniewski M, Collins JJ, Wormser GP (1992). "Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease". Annals of Internal Medicine. 117 (4): 273–80. doi:10.7326/0003-4819-117-4-273. PMID 1637021.
  26. Luger SW; Paparone P; Wormser GP; et al. (March 1995). "Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans". Antimicrob. Agents Chemother. 39 (3): 661–7. doi:10.1128/AAC.39.3.661. PMC 162601. PMID 7793869.
  27. Nadelman RB; Nowakowski J; Fish D; et al. (2001). "Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite". N. Engl. J. Med. 345 (2): 79–84. doi:10.1056/NEJM200107123450201. PMID 11450675.
  28. Karlsson M, Hammers-Berggren S, Lindquist L, Stiernstedt G, Svenungsson B (1994). "Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis". Neurology. 44 (7): 1203–7. doi:10.1212/WNL.44.7.1203. PMID 8035916.
  29. Weinstein RS (1996). "Human ehrlichiosis". Am Fam Physician. 54 (6): 1971–6. PMID 8900357.
  30. Karlsson U, Bjöersdorff A, Massung RF, Christensson B (2001). "Human granulocytic ehrlichiosis—a clinical case in Scandinavia". Scand. J. Infect. Dis. 33 (1): 73–4. doi:10.1080/003655401750064130. PMID 11234985.
  31. 31.0 31.1 31.2 31.3 31.4 31.5 U.S. Food and Drug Administration. 14 December 2012. Doxycycline, ANDA no. 065055 Label. Archived 19 April 2014 at the Wayback Machine
  32. 32.0 32.1 32.2 32.3 32.4 U.S. Food and Drug Administration. 16 July 2008.Doxycycline, ANDA no. 065454 Label Archived 19 October 2013 at the Wayback Machine
  33. Anderson A, Bijlmer H, Fournier PE, Graves S, Hartzell J, Kersh GJ, Limonard G, Marrie TJ, Massung RF, McQuiston JH, Nicholson WL, Paddock CD, Sexton DJ (2013). "Diagnosis and management of Q fever—United States, 2013: recommendations from CDC and the Q Fever Working Group". MMWR Recomm. Rep. 62 (RR-03): 1–30. PMID 23535757. Archived from the original on 19 April 2014.
  34. Okada T, Morozumi M, Tajima T, Hasegawa M, Sakata H, Ohnari S, Chiba N, Iwata S, Ubukata K (2012). "Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children". Clin Infect Dis. 55 (12): 1642–9. doi:10.1093/cid/cis784. PMID 22972867.
  35. "Lyme disease. Treatment". 21 December 2018. Archived from the original on 10 June 2016.
  36. B, Dreno; D, Thiboutot; H, Gollnick; V, Bettoli; S, Kang; Jj, Leyden; A, Shalita; V, Torres (2014). "Antibiotic Stewardship in Dermatology: Limiting Antibiotic Use in Acne". European journal of dermatology : EJD. PMID 24721547. Archived from the original on 7 June 2020. Retrieved 2020-06-07.
  37. William Cameron. "Comparison of doxycycline–streptomycin, doxycycline–rifampin, and ofloxacin–rifampin in the treatment of brucellosis: a randomized clinical trial". Archived from the original on 28 August 2021. Retrieved 23 August 2014.
  38. "Archive copy" (PDF). Archived (PDF) from the original on 6 December 2019. Retrieved 13 January 2019.{{cite web}}: CS1 maint: archived copy as title (link)
  39. "Malaria - Chapter 3 - 2018 Yellow Book | Travelers' Health | CDC". CDC. Archived from the original on 3 December 2018. Retrieved 4 December 2018.
  40. Dahl EL, Shock JL, Shenai BR, Gut J, DeRisi JL, Rosenthal PJ (2006). "Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum". Antimicrob. Agents Chemother. 50 (9): 3124–31. doi:10.1128/AAC.00394-06. PMC 1563505. PMID 16940111.
  41. Guidelines for the treatment of malaria. Geneva: World Health Organization. 2015. p. 246. ISBN 978-92-4-154912-7.
  42. Hoerauf A, Mand S, Fischer K, et al. (2003). "Doxycycline as a novel strategy against bancroftian filariasis-depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria production". Med. Microbiol. Immunol. 192 (4): 211–6. doi:10.1007/s00430-002-0174-6. PMID 12684759.
  43. Taylor MJ, Makunde WH, McGarry HF, Turner JD, Mand S, Hoerauf A (2005). "Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial". Lancet. 365 (9477): 2116–21. doi:10.1016/S0140-6736(05)66591-9. PMID 15964448.
  44. "Doxycycline hyclate Susceptibility and Minimum Inhibitory Concentration (MIC) Data" (PDF). Archived (PDF) from the original on 24 February 2015. Retrieved April 16, 2017.
  45. Kaufman, John A.; Lee, Michael J. Vascular and interventional radiology (2nd ed.). Philadelphia, PA. ISBN 978-0-323-07672-2. OCLC 853455295.
  46. 46.0 46.1 "Doxycycline - WikEM". Archived from the original on 25 September 2020. Retrieved 5 August 2020.
  47. 47.0 47.1 47.2 "DOXYCYCLINE oral - Essential drugs". Archived from the original on 28 August 2021. Retrieved 30 August 2020.
  48. "How to Make Liquid Doxycycline" (PDF). Archived (PDF) from the original on 25 July 2023. Retrieved 1 December 2023.
  49. 49.0 49.1 Hitchings, Andrew; Lonsdale, Dagan; Burrage, Daniel; Baker, Emma (2015). Top 100 drugs : clinical pharmacology and practical prescribing. pp. 200–201. ISBN 978-0-7020-5516-4.
  50. 50.0 50.1 Riond, JL; Riviere, JE (October 1988). "Pharmacology and toxicology of doxycycline". Veterinary and Human Toxicology. 30 (5): 431–43. PMID 3055652.
  51. Affolter K, Samowitz W, Boynton K, Kelly ED (August 2017). "Doxycycline-induced gastrointestinal injury". Hum. Pathol. 66: 212–215. doi:10.1016/j.humpath.2017.02.011. PMID 28286288.
  52. Hung YP, Lee JC, Lin HJ, Liu HC, Wu YH, Tsai PJ, Ko WC (June 2015). "Doxycycline and Tigecycline: Two Friendly Drugs with a Low Association with Clostridium Difficile Infection". Antibiotics. 4 (2): 216–29. doi:10.3390/antibiotics4020216. PMC 4790331. PMID 27025622.
  53. Center for Global Health; Centers for Disease Control and Prevention (2011). "Doxycycline for Malaria Chemoprophylaxis and Treatment: Report from the CDC Expert Meeting on Malaria Chemoprophylaxis". The American Journal of Tropical Medicine and Hygiene. 84 (4): 517–531. doi:10.4269/ajtmh.2011.10-0285. PMC 3062442. PMID 21460003.[verification needed]
  54. Center for Drug Evaluation and Research (November–December 2004). "European recommendations on the use of oral antibiotics for acne". European Journal of Dermatology. 14 (6): 391–399. Archived from the original on 29 May 2007. Retrieved 31 January 2008.[verification needed]
  55. Chung, AM; Reed, MD; Blumer, JL (2002). "Antibiotics and breast-feeding: a critical review of the literature". Paediatric Drugs. 4 (12): 817–37. doi:10.2165/00128072-200204120-00006. PMID 12431134.
  56. Mylonas, I (January 2011). "Antibiotic chemotherapy during pregnancy and lactation period: aspects for consideration". Archives of Gynecology and Obstetrics. 283 (1): 7–18. doi:10.1007/s00404-010-1646-3. PMID 20814687.
  57. "Bioterrorism and Drug Preparedness - Doxycycline Use by Pregnant and Lactating Women". FDA. 3 November 2018. Archived from the original on 8 February 2019. Retrieved 9 December 2018.
  58. Gaillard T, Briolant S, Madamet M, Pradines B (April 2017). "The end of a dogma: the safety of doxycycline use in young children for malaria treatment". Malar. J. 16 (1): 148. doi:10.1186/s12936-017-1797-9. PMC 5390373. PMID 28407772.
  59. 59.0 59.1 59.2 59.3 Haberfeld H, ed. (2020). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Doxycyclin Genericon 200 mg lösliche Tabletten.{{cite book}}: CS1 maint: unrecognized language (link)
  60. PubMed Health (1 July 2016). "Doxycycline (By mouth)". U.S. National Library of Medicine. Archived from the original on 11 November 2013. Retrieved 16 July 2016.
  61. Kshirsagar N A, Ankalesaria P S. Effect of food on doxycycline absorption. J Postgrad Med (serial online) 1987 (cited 2016 Jul 16);33:117. Available from: Archived 18 August 2016 at the Wayback Machine
  62. Archer JS, Archer DF (2002). "Oral contraceptive efficacy and antibiotic interaction: a myth debunked". J. Am. Acad. Dermatol. 46 (6): 917–23. doi:10.1067/mjd.2002.120448. PMID 12063491.
  63. Dréno B, Bettoli V, Ochsendorf F, Layton A, Mobacken H, Degreef H (November–December 2004). "European recommendations on the use of oral antibiotics for acne" (PDF). Eur J Dermatol. 14 (6): 391–9. PMID 15564203.[permanent dead link]
  64. DeRossi SS, Hersh EV (2002). "Antibiotics and oral contraceptives". Dent. Clin. North Am. 46 (4): 653–64. CiteSeerX doi:10.1016/S0011-8532(02)00017-4. PMID 12436822.
  65. Flower, R.; Rang, H. P.; Dale, M. M.; Ritter, J. M.; Henderson, G. (2012). Rang & Dale's Pharmacology. Edinburgh: Churchill Livingstone. ISBN 978-0-7020-3471-8.
  66. 66.0 66.1 Maaland, MG; Papich, MG; Turnidge, J; Guardabassi, L (November 2013). "Pharmacodynamics of doxycycline and tetracycline against Staphylococcus pseudintermedius: proposal of canine-specific breakpoints for doxycycline". Journal of Clinical Microbiology. 51 (11): 3547–54. doi:10.1128/JCM.01498-13. PMC 3889732. PMID 23966509.
  67. Agwuh, KN; MacGowan, A (2006). "Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines". J. Antimicrob. Chemother. 58 (2): 256–265. doi:10.1093/jac/dkl224. PMID 16816396.
  68. "Doxycycline". Archived from the original on 10 November 2008. Retrieved 23 January 2019.
  69. 69.0 69.1 69.2 Dinnendahl, V; Fricke, U, eds. (2010). Arzneistoff-Profile (in German). Vol. 4 (24 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. Doxycyclin. ISBN 978-3-7741-9846-3.{{cite book}}: CS1 maint: unrecognized language (link)
  70. 70.0 70.1 Doxycycline Professional Drug Facts. Accessed 2020-08-05.
  71. "Principles and methods for the assessment of nephrotoxicity associated with exposure to chemicals" Archived 10 May 2011 at the Wayback Machine. Environmental health criteria: 119. World Health Organization (WHO). ISBN 92-4-157119-5. ISSN 0250-863X. 1991.
  72. 72.0 72.1 Foye's Principles of Medicinal Chemistry; David A. Williams; William O. Foye, Thomas L. Lemke
  73. 73.0 73.1 Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12ed, Laurence L. Brunton, Bruce A. Chabner, Björn C. Knollmann
  74. 74.0 74.1 Nelson ML, Levy SB (Dec 2011). "The history of the tetracyclines". Ann N Y Acad Sci. 1241 (1): 17–32. Bibcode:2011NYASA1241...17N. doi:10.1111/j.1749-6632.2011.06354.x. PMID 22191524.
  75. Pfizer, Inc. v. International Rectifier Corp., 545 F. Supp. 486 (C.D. Cal. 1980) Archived 24 February 2015 at the Wayback Machine
  76. 76.0 76.1 The Associated Press, 6 July 1983 "Pfizer to Get Rachelle Units" Archived 6 March 2016 at the Wayback Machine The New York Times.
  77. CDC Health Alert Network 12 June 2013 Nationwide Shortage of Doxycycline: Resources for Providers and Recommendations for Patient Care Archived 15 February 2015 at the Wayback Machine
  78. American Society of Health-System Pharmacists. 12 December 2014 Doxycycline Capsules and Tablets Archived 1 January 2015 at the Wayback Machine
  79. American Society of Health-System Pharmacists. 12 November 2014 Doxycycline Hyclate Injection Archived 1 January 2015 at the Wayback Machine
  80. Consumer Reports News: 4 February 2013 FDA reports shortage of doxycycline antibiotic. What are your options? Archived 1 January 2015 at the Wayback Machine
  81. Sudden increase in cost of common drug concerns many Archived 31 December 2014 at the Wayback Machine, WSMV-TV, 12 March 2013 (updated 26 March 2013).
  82. Rosenthal, Elisabeth, Officials Question the Rising Costs of Generic Drugs Archived 23 February 2017 at the Wayback Machine, The New York Times, 7 October 2014.
  83. Eric Palmer for FiercePharmaManufacturing. 13 March 2014 Hikma hits the jackpot with doxycycline shortage Archived 1 January 2015 at the Wayback Machine
  84. "Costco Drug Information". Archived from the original on 4 March 2016. Retrieved 31 July 2016.
  85. "Doxycycline Hyclate Prices and Doxycycline Hyclate Coupons". GoodRx. Archived from the original on 28 July 2016. Retrieved 31 July 2016.
  86. "NADAC as of 2019-09-11 |". Centers for Medicare and Medicaid Services. Archived from the original on 30 December 2019. Retrieved 10 September 2019.
  87. international availability for doxycycline Archived 16 May 2015 at the Wayback Machine Page accessed April 29, 2015
  88. 88.0 88.1 88.2 BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 597-599. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
  89. Dalvi PS; Singh A; Trivedi HR; et al. (2011). "Effect of doxycycline in patients of moderate to severe chronic obstructive pulmonary disease with stable symptoms". Ann Thorac Med. 6 (4): 221–6. doi:10.4103/1817-1737.84777. PMC 3183640. PMID 21977068.
  90. Leung, E; Landa, G (September 2013). "Update on current and future novel therapies for dry age-related macular degeneration". Expert Review of Clinical Pharmacology. 6 (5): 565–79. doi:10.1586/17512433.2013.829645. PMID 23971874.
  91. Saraiva IH, Jones RN, Erwin M, Sader HS (1997). "[Evaluation of antimicrobial sensitivity of 87 clinical isolates of vancomycin-resistant enterococci]". Rev Assoc Med Bras (in Portuguese). 43 (3): 217–22. doi:10.1590/S0104-42301997000300009. PMID 9497549.{{cite journal}}: CS1 maint: unrecognized language (link)
  92. Dibb WL, Digranes A (1981). "Characteristics of 20 human Pasteurella isolates from animal bite wounds". Acta Pathol Microbiol Scand [B]. 89 (3): 137–41. PMID 7315339.
  93. Greenwald RA (December 2011). "The road forward: the scientific basis for tetracycline treatment of arthritic disorders". Pharmacol. Res. 64 (6): 610–3. doi:10.1016/j.phrs.2011.06.010. PMID 21723947.
  94. Raza M, Ballering JG, Hayden JM, Robbins RA, Hoyt JC (2006). "Doxycycline decreases monocyte chemoattractant protein-1 in human lung epithelial cells". Exp. Lung Res. 32 (1–2): 15–26. doi:10.1080/01902140600691399. PMID 16809218.
  95. Chodosh S, Tuck J, Pizzuto D (1988). "Comparative trials of doxycycline versus amoxicillin, cephalexin and enoxacin in bacterial infections in chronic bronchitis and asthma". Scand J Infect Dis Suppl. 53: 22–8. PMID 3047855.
  96. Joks R, Durkin HG (December 2011). "Non-antibiotic properties of tetracyclines as anti-allergy and asthma drugs". Pharmacol. Res. 64 (6): 602–9. doi:10.1016/j.phrs.2011.04.001. PMID 21501686.
  97. Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L (2001). "The use of tetracyclines for the treatment of sarcoidosis". Arch Dermatol. 137 (1): 69–73. doi:10.1001/archderm.137.1.69. PMID 11176663. Archived from the original on 7 April 2008.
  98. El Sayed F, Dhaybi R, Ammoury A (2006). "Subcutaneous nodular sarcoidosis and systemic involvement successfully treated with doxycycline". J Med Liban. 54 (1): 42–4. PMID 17044634.
  99. Mishra GP, Mulani JD. "Doxycycline: An Old Drug With A New Role In Idiopathic Pulmonary Fibrosis" Archived 23 July 2011 at the Wayback Machine. International Journal of Pharma and Bio Sciences. V1(2) 2010. ISSN 0975-6299.
  100. Moullan N, Mouchiroud L, Wang X, Ryu D, Williams EG, Mottis A, Jovaisaite V, Frochaux MV, Quiros PM, Deplancke B, Houtkooper RH, Auwerx J (2015). "Tetracyclines Disturb Mitochondrial Function across Eukaryotic Models: A Call for Caution in Biomedical Research". Cell Reports. 10 (10): 1681–91. doi:10.1016/j.celrep.2015.02.034. PMC 4565776. PMID 25772356.
  101. Chatzispyrou IA, Held NM, Mouchiroud L, Auwerx J, Houtkooper RH (2015). "Tetracycline antibiotics impair mitochondrial function and its experimental use confounds research". Cancer Research. 75 (21): 4446–9. doi:10.1158/0008-5472.CAN-15-1626. PMC 4631686. PMID 26475870.
  102. 102.0 102.1 Gossen M, Freundlieb S, Bender G, Müller G, Hillen W, Bujard H (1995). "Transcriptional activation by tetracyclines in mammalian cells". Science. 268 (5218): 1766–1769. Bibcode:1995Sci...268.1766G. doi:10.1126/science.7792603. PMID 7792603.
  103. Dursun D, Kim MC, Solomon A, Pflugfelder SC (2001). "Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids". Am. J. Ophthalmol. 132 (1): 8–13. doi:10.1016/S0002-9394(01)00913-8. PMID 11438047.

External links